SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company specialized in the development of novel cancer immunotherapies for a broad range of cancer indications. The company, incorporated in 2012 and headquartered in New York City, is listed on the NASDAQ under the ticker symbol "SLS".
SELLAS’ mission is to develop innovative treatments for cancer patients worldwide, with a focus on advancing immunotherapeutics and providing new therapeutic options for patients whose cancers are not responsive to current standard oncology treatments. The company uses a precision medicine approach to develop its products, identifying the unique genetic or protein changes in a patient’s cancer and designing therapies to specifically target these changes.
Their lead product candidate is galinpepimut-S (GPS), an immunotherapeutic agent that is in various stages of development for multiple types of cancer, including acute myeloid leukemia (AML), multiple myeloma (MM), and ovarian cancer. The therapy has obtained fast track and orphan drug designations from the FDA for these indications.
SELLAS also develops nelipepimut-S (NPS), an investigational immunotherapy that targets the HER2/neu protein. NPS is being developed for the treatment of patients with breast cancer that express the HER2/neu protein.
The development of these innovative cancer treatments speaks to the company's commitment to scientific and clinical excellence. Although the company is still in the clinical phase, these advancements in the pipeline demonstrate a promising trajectory.
The Company's management and board have noteworthy tenures within the pharmaceutical industry, bringing valuable experience and knowledge, making SELLAS Life Sciences Group well positioned to bring these new cancer treatments to market.
The company's strategy includes partnerships with well-established pharmaceutical companies to ensure they have the resources necessary to complete the expensive clinical phase. Over the years, SELLAS has established itself within the oncology space through peer-reviewed publications and presentations at top oncology conferences.
SELLAS Life Sciences Group, Inc. (SLS) adheres to stringent ethical, scientific, and clinical standards in their research and development process. They are driven by a commitment to innovation and the ambition to improve the lives of patients who are battling cancer. The company's work in advancing cancer research and drug development represents its pledge to make a significant difference in the field of oncology.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
SELLAS Life Sciences Group (Nasdaq: SLS) announced that its pivotal Phase III REGAL trial for galinpepimut-S (GPS), an immunotherapy for acute myeloid leukemia (AML), has finally reached the 80th death milestone, triggering its final overall survival analysis. This achievement, nearly 10 months later than anticipated, has fueled speculation about GPS's survival benefit, with topline efficacy results expected in Q4 2026. The trial addresses a significant unmet need for AML patients in second complete remission who cannot undergo allogeneic stem cell transplantation.
SELLAS Life Sciences Group Inc (NASDAQ: SLS) shares fell after the company announced its Phase 3 REGAL trial for an acute myeloid leukemia immunotherapy reached the critical 80-death milestone, triggering the final analysis. While this is a significant step, the results of whether the experimental immunotherapy, galinpepimut-S (GPS), is effective in prolonging patient life are still unknown and are expected later this quarter. The stock's current decline reflects the uncertainty surrounding these upcoming top-line findings.
SELLAS Life Sciences Group announced that its Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML) has reached its pre-specified 80th event (death), triggering the final analysis. The company will now proceed with database lock, unblinding, and statistical analysis, with preliminary topline primary endpoint results expected to be announced this quarter. This milestone marks a critical step towards evaluating GPS as a potential maintenance therapy for AML patients.
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 15,872,685 shares in SELLAS Life Sciences Group Inc., representing 7.9% of the company's outstanding common stock as of September 30, 2026. The asset manager holds sole voting power over 15,499,019 shares and sole dispositive power over all reported shares, with no shared authority. This update reflects BlackRock's significant stake in the life sciences company.
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) saw its stock climb over 10% following the release of promising preclinical data for its CDK9 inhibitor SLS009 in pancreatic ductal adenocarcinoma models. The data highlighted SLS009's activity in difficult-to-treat, MYC-amplified, RAS-inhibitor–resistant disease and demonstrated synergy when combined with other inhibitors, creating a strong narrative for the development-stage biotech company. Despite current unprofitability, the company's substantial cash reserves and limited debt provide a runway for ongoing clinical work, positioning SLS as a speculative but news-driven trading opportunity.